HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

778

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions

First-line Treatment of Advanced Pancreatic Cancer

Interventions

DRUG

HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate

HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate

DRUG

nab-paclitaxel; gemcitabine

nab-paclitaxel in combination with gemcitabine

Trial Locations (1)

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY